{
    "medicine_id": "b575084e8376d6e7e33c43245fc61594079b19b0",
    "platform_id": "DB04873",
    "metadata": {
        "name": "Belviq 10 mg 1 Tablet",
        "composition": "10 mg 1 Piboserod",
        "clinical_particulars": {
            "therapeutic_indications": "For the treatment of atrial fibrillation and irritable bowel syndrome IBS",
            "contraindications": {
                "disease": "NA",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "GlaxoSmithKline was investigating piboserod a 5HT4 antagonist for the treatment of atrial fibrillation Phase II trials were ongoing in March 2004 but by December of that year development had been discontinued Piboserod had previously being investigated for the treatment of irritable bowel syndrome IBS but development for this indication was terminated in 1999",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}